**Supplementary Material**

**Table S1. Overlap propensity score–weighted baseline characteristics between two causes of chronic kidney disease**

In all sets, SMD was <0.001 for all variables

BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1C; HDL, high density lipid; Hs-CRP, high sensitivity-C reactive protein; IPTW, inverse probability of treatment weighting; LDL, low density lipid; SMD; standardized mean difference

**Table S1. Overlap propensity score–weighted baseline characteristics between two causes of chronic kidney disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Glomerulonephritis** | **Hypertensive nephropathy** | **Glomerulonephritis** | **Diabetic Nephropathy** | **Glomerulonephritis** | **Polycystic kidney disease** | **Hypertensive nephropathy** | **Diabetic Nephropathy** | **Hypertensive nephropathy** | **Polycystic kidney disease** | **Diabetic Nephropathy** | **Polycystic kidney disease** |
|  | **Set 1** | **Set 2** | **Set 3** | **Set 4** | **Set 5** | **Set 6** |
|  | 163.50 | 163.50 | 152.67 | 152.67 | 127.49 | 127.49 | 124.17 | 124.17 | 92.06 | 92.06 |  41.47 |  41.47 |
| **Age, years** | 56.3 ± 11.3 | 56.3 ± 10.4 | 57.1 ± 9.7 | 57.1 ± 10.7 | 48.6 ± 10.9 | 48.6 ± 12.1 | 60.5 ± 8.8 | 60.5 ± 10.7 | 54.1 ± 9.1 | 54.1 ±11.3 | 55.3 ± 9.3 | 55.3 ± 9.9 |
| **Female, %** | 35.6 | 35.6 | 37.4 | 37.4 | 44.9 | 44.9 | 32.8 | 32.8 | 37.5 | 37.5 | 45.6 | 45.6 |
| **BMI, kg/m2** | 24.7 ± 3.1 | 24.7 ± 3.1 | 24.9 ± 3.3 | 24.7 ± 3.6 | 23.7 ± 3.0 | 23.7 ± 3.2 | 25.3 ± 3.1 | 25.3 ± 3.7 | 24.3 ± 2.8 | 24.3 ± 3.8 | 24.1 ± 2.9 | 24.1 ± 2.8 |
| **Mean blood pressure, mmHg** | 93.1 ± 11.9 | 93.1 ± 10.5 | 93.1 ±11.4 | 93.1 ±10.2 | 94.5 ±10.0 | 94.5 ±11.5 | 94.4 ± 12.5 | 94.4 ± 12.2 | 95.2 ± 10.3 | 95.2 ± 11.9 | 94.6 ± 10.7 | 94.6 ± 13.8 |
| **Prevalence of cardiovascular disease, %** | 15.4 | 15.4 | 17.3 | 17.3 | 7.5 | 7.5 | 25.6 | 25.6 | 11.4 | 11.4 | 14.3 | 14.3 |
| **eGFR, ml/min/1.73m2**  | 44.3 ± 24.6 | 44.3 ± 23.7 | 44.5 ± 26.2 | 44.5 ± 26.8 | 62.5 ± 31.4 | 62.5 ± 32.0 | 38.6 ± 38.6 | 38.6 ± 23.1 | 47.9 ± 24.5 | 47.9 ± 26.3 | 46.7 ± 27.2 | 46.7 ± 27.0 |
| **Chronic kidney disease stage** |  |  |  |  |  |  |  |  |  |  |  |  |
|  | **G1, %** | 6.5 | 6.5 | 9.0 | 9.0 | 24.3 | 4.8 | 4.8 | 7.3 | 7.3 | 8.8 | 8.8 | 8.8 |
|  | **G2, %** | 15.9 | 15.9 | 14.3 | 14.3 | 25.7 | 9.6 | 9.6 | 19.7 | 19.7 | 18.8 | 18.8 | 18.8 |
|  | **G3a, %** | 19.6 | 19.6 | 15.9 | 15.9 | 14.5 | 15.6 | 15.6 | 22.6 | 22.6 | 16.5 | 16.5 | 16.5 |
|  | **G3b, %** | 25.6 | 25.6 | 24.7 | 24.7 | 16.8 | 26.8 | 26.8 | 22.3 | 22.3 | 21.9 | 21.9 | 21.9 |
|  | **G4, %** | 25.0 | 25.0 | 26.9 | 26.9 | 13.6 | 33.3 | 33.3 | 20.0 | 20.0 | 23.8 | 23.8 | 23.8 |
|  | **G5, %** | 7.4 | 7.4 | 9.1 | 9.1 | 5.1 | 10.0 | 10.0 | 8.0 | 8.0 | 10.1 | 10.1 | 10.1 |
| **Hemoglobin, g/dL** | 13.1 ±2.1 | 13.1 ± 1.9 | 12.2 ± 1.9 | 12.2 ± 1.8 | 13.1 ± 1.9 | 13.1 ± 1.8 | 12.4 ± 1.9 | 12.4 ± 1.9 | 13.1 ± 1.9 | 13.1 ± 2.0 | 12.2 ± 2.1 | 12.2 ± 1.8 |
| **Uric acid, mg/dL** | 7.4 ± 1.7 | 7.4 ± 2.0 | 7.2 ± 1.9 | 7.2 ± 1.9 | 6.6 ± 1.8 | 6.6 ± 1.9 | 7.4 ± 1.9 | 7.4 ± 1.8 | 7.1 ± 1.7 | 7.7 ± 1.8 | 6.8 ± 1.6 | 6.8 ± 1.8 |
| **Calcium, mg/dL** | 9.2 ± 0.5 | 9.2 ± 0.5 | 9.0 ± 0.6 | 9.0 ± 0.5 | 9.2 ± 0.5 | 9.2 ± 0.4 | 9.1 ± 0.6 | 9.1 ± 0.5 | 9.2 ± 0.5 | 9.2 ± 0.5 | 9.1 ± 0.5 | 9.1 ± 0.6 |
| **Phosphorous, mg/dL** | 3.6 ± 0.7 | 3.6 ± 0.6 | 3.8 ± 0.7 | 3.8 ± 0.7 | 3.6 ± 0.6 | 3.6 ± 0.6 | 3.7 ± 0.7 | 3.7 ± 0.7 | 3.7 ± 0.6 | 3.7 ± 0.7 | 3.8 ± 0.7 | 3.8 ± 0.7 |
| **Albumin, g/dL** | 4.3 ± 0.4 | 4.3 ± 0.3 | 4.1 ± 0.5 | 4.1 ± 0.4 | 4.3 ± 0.3 | 4.3 ± 0.3 | 4.2 ± 0.4 | 4.2 ± 0.4 | 4.4 ± 0.3 | 4.4 ± 0.3 | 4.3 ± 0.3 | 4.3 ± 0.3 |
| **Total Cholesterol, mg/dL** | 171.3 ± 37.2 | 171.3 ± 34.1 | 170.8 ±43.5 | 170.8 ±36.8 | 174.6 ± 34.9 | 174.6 ± 33.0 | 165.0 ± 38.1 | 165.0 ± 36.7 | 171.5 ± 37.1 | 171.5 ± 34.8 | 164.0 ± 36.3 | 164.0 ± 36.8 |
| **HDL-cholesterol, mg/dL** | 48.2 ± 15.0 | 48.2 ±14.2 | 46.4 ±15.5 | 46.4 ± 12.6 | 51.6 ± 13.9 | 51.6 ± 15.7 | 45.7 ± 15.8 | 45.7 ± 12.5 | 49.7 ± 14.0 | 49.7 ± 15.5 | 48.2 ± 13.3 | 48.2 ± 16.5 |
| **LDL-cholesterol, mg/dL** | 94.4 ± 31.0 | 94.4 ± 28.4 | 93.4 ±35.0 | 93.4 ± 29.4 | 98.3 ± 26.5 | 98.3 ± 29.7 | 90.2 ± 30.7 | 90.2 ± 29.6 | 94.7 ± 26.3 | 94.7 ± 30.4 | 89.8 ± 24.3 | 89.8 ± 33.8 |
| **Fasting blood sugar, mg/dL** | 104.5 ± 22.7 | 104.5 ±27.2 | 115.7 ± 38.3 | 115.7 ± 48.8 | 97.5 ± 11.3 | 97.5 ± 17.3 | 114.0 ± 33.8 | 114.0 ± 38.5 | 99.6 ± 12.5 | 99.6 ± 13.2 | 101.3 ± 13.5 | 101.3 ± 28.6 |
| **Log (parathyroid hormone, pg/mL)** | 4.1 ± 0.7 | 4.1 ± 0.7 | 4.1 ± 0.7 | 4.1 ± 0.7 | 3.9 ± 0.7 | 3.9 ± 0.7 | 4.2 ± 0.7 | 4.2 ± 0.7 | 4.1 ± 0.7 | 4.1 ± 0.7 | 4.1 ± 0.8 | 4.1 ± 0.7 |
| **Log (urine Protein/creatinine, g/g Cr)** | -0.9 ± 1.4 | -0.9 ±1.3 | -0.1 ± 1.4 | -0.1 ±1.3 | -0.5 ± 1.5 | -0.5 ± 1.2 | -0.6 ± 1.3 | -0.6 ± 1.2 | -1.8 ± 1.1 | -1.8 ± 1.5 | -1.2 ± 1.1 | -1.2 ± 1.2 |
| **Log (hs-CRP, mg/dL)** | -0.3 ± 1.4 | -0.3 ± 1.3 | -0.4 ± 1.2 | -0.4 ± 1.2 | -0.5 ± 1.5 | -0.5 ± 1.2 | -0.3 ± 1.3 | -0.3 ± 1.4 | -0.4 ± 1.5 | -0.4 ± 1.3 | -0.5 ± 1.6 | -0.5 ± 1.2 |
| **Diuretics use, %** | 32.6 | 32.6 | 41.8 | 41.8 | 15.4 | 15.4 | 44.9 | 44.9 | 20.8 | 20.8 | 26.6 | 26.6 |
| **Statin use, %** | 54.1 | 54.1 | 60.3 | 60.3 | 33.2 | 33.2 | 60.9 | 60.9 | 45.7 | 45.7 | 49.5 | 49.5 |
| **ACEI or ARB use** | 85.5 | 85.5 | 89.1 | 89.1 | 84.5 | 84.5 | 86.9 | 86.9 | 84.3 | 84.3 | 88.9 | 88.9 |

In all sets, SMD <0.001 for all variables

BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1C; HDL, high density lipid; Hs-CRP, high sensitivity-C reactive protein; IPTW, inverse probability of treatment weighting; LDL, low density lipid; SMD; standardized mean difference